Australia · Delayed Price · Currency is AUD Ligand Pharmaceuticals Statistics
Total Valuation
ASX:TGF has a market cap or net worth of AUD 109.91 million. The enterprise value is -106.88 million.
| Market Cap | 109.91M |
| Enterprise Value | -106.88M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
ASX:TGF has 78.79 million shares outstanding. The number of shares has increased by 5.35% in one year.
| Current Share Class | 78.79M |
| Shares Outstanding | 78.79M |
| Shares Change (YoY) | +5.35% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 5.94% |
| Owned by Institutions (%) | 5.43% |
| Float | 72.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -60.33 |
| PB Ratio | 0.71 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 4.42 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 11.47 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.63
| Current Ratio | 2.63 |
| Quick Ratio | 2.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.11 |
Financial Efficiency
Return on equity (ROE) is -5.87% and return on invested capital (ROIC) is -2.03%.
| Return on Equity (ROE) | -5.87% |
| Return on Assets (ROA) | -1.35% |
| Return on Invested Capital (ROIC) | -2.03% |
| Return on Capital Employed (ROCE) | -3.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.00% in the last 52 weeks. The beta is 0.92, so ASX:TGF's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -7.00% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | 1.45 |
| Relative Strength Index (RSI) | 36.86 |
| Average Volume (20 Days) | 152,510 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ASX:TGF had revenue of AUD -1.82 million and -9.31 million in losses. Loss per share was -0.12.
| Revenue | -1.82M |
| Gross Profit | -1.82M |
| Operating Income | -5.14M |
| Pretax Income | -13.91M |
| Net Income | -9.31M |
| EBITDA | n/a |
| EBIT | -5.14M |
| Loss Per Share | -0.12 |
Balance Sheet
The company has 216.80 million in cash and n/a in debt, giving a net cash position of 216.80 million or 2.75 per share.
| Cash & Cash Equivalents | 216.80M |
| Total Debt | n/a |
| Net Cash | 216.80M |
| Net Cash Per Share | 2.75 |
| Equity (Book Value) | 153.90M |
| Book Value Per Share | 1.95 |
| Working Capital | 135.13M |
Cash Flow
| Operating Cash Flow | 24.86M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | 282.18% |
| Pretax Margin | 763.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ASX:TGF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.35% |
| Shareholder Yield | n/a |
| Earnings Yield | -8.47% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ASX:TGF has an Altman Z-Score of 1.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.3 |
| Piotroski F-Score | 2 |